Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term implantable continuous glucose monitoring systems for diabetes patients, has scheduled its second quarter 2025 earnings release and conference call for August 6, 2025.
The financial results will be released after market close, followed by a management conference call at 4:30 PM Eastern Time. Investors can access the call via phone (US/Canada: 1-800-225-9448, International: 1-203-518-9708, passcode: SENSQ2) or through a webcast available on the company's investor relations website.
Details
News Market Reaction – SENS
The recorded move for SENS in the trading session of this news was +4.98%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, August 6, 2025.
Management will hold a conference call to review the Company’s second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-225-9448 (US/Canada) or 1-203-518-9708 (International), passcode SENSQ2, approximately ten to five minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.